

December 11, 2015



# Endonovo Therapeutics Buys Back Convertible Note From Lender Avoiding Any Immediate Dilution

**Endonovo Therapeutics Is Working With a Long-Term Company Investor to Redeem and Restructure the Remaining Convertible Notes on Better Terms in an Ongoing Effort to Protect Shareholder Value**

LOS ANGELES, CA -- (Marketwired) -- 12/11/15 -- [Endonovo Therapeutics, Inc.](#) (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced that it has paid in full a convertible promissory note with Vis Vires Group, Inc. for \$56,590.85 avoiding any immediate dilution.

Endonovo is also working with several new investors as well as a top tier New York Investment Bank to secure a larger round of financing to complete its pre-clinical work and explore licensing and potential revenue producing applications of its technologies.

Alan Collier, Chairman and CEO, commented, "We remain committed to increasing shareholder value and avoiding immediate shareholder dilution. This represents a significant first step toward consolidating and eliminating our convertible debt. As a result, this provides the company flexibility as it continues to work on obtaining a larger round of institutional financing. We are vigilant when it comes to protecting our shareholders' interest while we progress towards the commercialization of the company's two leading platforms."

## ***About Endonovo Therapeutics***

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.

Investors: [Sign Up for Email Alerts](#) on Endonovo

## ***Safe Harbor Statement***

This press release contains information that constitutes forward-looking statements made

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

***Investor Relations Contact:***

Endonovo Therapeutics, Inc.

Mr. Steven Barnes

Vice President of Investor Relations

(800) 701-1223, Ext. 108

[Sbarnes@endonovo.com](mailto:Sbarnes@endonovo.com)

[www.endonovo.com](http://www.endonovo.com)

Source: Endonovo Therapeutics, Inc.